NCT04185831View on ClinicalTrials.gov

A MolEcularly Guided Anti-Cancer Drug Off-Label Trial

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

167

Participants

Timeline

Start Date

October 20, 2020

Primary Completion Date

January 31, 2024

Study Completion Date

October 31, 2024

Conditions

Solid Tumor

Interventions

DRUG

Atezolizumab

PD-L1 inhibitor

DRUG

Everolimus

MTOR inhibitor

DRUG

Cobimetinib

MEK inhibitor

DRUG

Niraparib

PARP inhibitor

Trial Locations (3)

Unknown

Sahlgrenska University Hospital, Gothenburg

Skane University Hospital, Lund

Uppsala University Hospital, Uppsala

All Listed Sponsors

lead

Uppsala University Hospital

OTHER